<DOC>
	<DOCNO>NCT01435369</DOCNO>
	<brief_summary>The purpose research study see study drug , CT-011 , safe give help people melanoma spread area body . CT-011 monoclonal antibody . Monoclonal antibody type drug typically give infusion vein ( intravenously ) . Monoclonal antibody antibody make lab instead immune system recruit immune system help fight cancer cell . All final eligible subject receive intravenous infusion CT-011 . This study test two dose level study drug : Group 1 : Patients group give study drug dose level 1 ( 1.5 mg/kg ) . Group 2 : Patients group give study drug dose level 2 ( 6.0 mg/kg ) . Each group give study drug IV ( needle put vein arm ) day 1 . After day 1 , study drug give every week . Patients may give total 27 study drug infusion 12 month study . Approximately 100 patient participate study .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Study Monoclonal Antibody , CT-011 , Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Participants must histologically cytologically document diagnosis metastatic melanoma . 2 . Participants age 18 year old . 3 . Stage IV disease clearly progressive since last therapy 4 . ECOG performance status 0 1 . 1 . Patients uveal melanoma . 2 . Active autoimmune disease , symptoms condition except vitiligo , type I diabetes , treat thyroiditis , asymptomatic laboratory evidence autoimmune disease ( eg : + ANA , +RF , antithyroglobulin antibody ) mild arthritis require therapy manageable NSAIDs . 3 . Prior use anti PD1 , anti PDL1 PDL2 therapy . 4 . More 3 prior line treatment metastatic melanoma include approve investigational treatment . 5 . Women child bear potential pregnant Note : This partial list eligibility criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>